#United States #New York #Class Action #Levi Korsinsky #Zenas BioPharma

Zenas BioPharma, Inc. Class Action Lawsuit Updates

On May 13, 2025, Levi & Korsinsky, LLP announced updates regarding a pending class action lawsuit involving Zenas BioPharma, Inc. (NASDAQ: ZBIO). This legal action aims to compensate investors who may have suffered financial losses due to alleged securities fraud related to the company's public offerings. The firm, renowned for its successful track record in litigation, aims to ensure that affected investors have the opportunity to recover their losses.

Background of the Lawsuit

The lawsuit addresses claims that Zenas BioPharma misled investors regarding its financial situation, particularly during its initial public offering (IPO) in September 2024. Class action suits like this are typically filed when a significant number of investors are impacted by similar alleged misrepresentations or omissions of critical information by the company. In this instance, the complaint alleges that Zenas BioPharma overstated its financial stability, particularly the length of time it could sustain operations with its available cash reserves and the anticipated net proceeds from the IPO.

Key Allegations

The core allegations can be summarized as follows:
1. Overstatement of Financial Stability: The defendants purportedly inflated the time frame that the company could continue operations, leading investors to believe that Zenas BioPharma was in a stronger fiscal position than it actually was.
2. Misleading Information: Public statements made by Zenas BioPharma are claimed to be materially false and misleading, which resulted in poor investment decisions by shareholders.

These issues have raised serious concerns for investors, prompting them to take action to seek restitution through legal means. As the case progresses, the focus will likely remain on uncovering how these misrepresentations impacted stock prices and investor confidence.

Class Member Rights and Deadlines

Investors who believe they have been adversely affected by Zenas BioPharma's statements have the opportunity to join the class action. The critical deadline to act as the lead plaintiff in this case is June 16, 2025. However, it's important to note that sharing in any potential recovery does not require one to serve as a lead plaintiff. What this means is that all class members are eligible to seek compensation for their financial losses.

No Financial Risk for Investors

Levi & Korsinsky emphasizes that investors can participate in this legal process without incurring any out-of-pocket expenses. The law firm operates on a contingency fee basis, meaning that class members do not need to worry about the cost of legal fees upfront. This structure is designed to encourage participation from investors who may have lost money following the alleged misconduct of Zenas BioPharma.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has been a prominent player in securities litigation for over two decades, securing significant settlements for shareholders impacted by securities fraud. They have built a solid reputation as one of the leading firms in this field, consistently ranking high in ISS Securities Class Action Services Top 50 Report for several consecutive years. Their dedicated team of legal professionals specializes in complex securities issues, ensuring that investors are well-represented.

Contact Information

For more details regarding participation in the class action or to inquire about your rights as an investor, you can reach out to:

• - Joseph E. Levi, Esq. at email protected] or call (212) 363-7500.
• - Company Website: [Levi & Korsinsky

Conclusion

The class action lawsuit against Zenas BioPharma is ongoing, and investors are urged to stay informed about their rights as potential class members. With a firm like Levi & Korsinsky at the helm, investors can navigate this complex legal landscape with the reassurance that expert assistance is available. It’s crucial to act swiftly if you believe you have been affected by this situation, especially with the deadline quickly approaching. By coming together as a class, affected individuals stand a better chance of recovering their losses and holding companies accountable for their actions.